Medicamen Organics Ltd
MEDIORG NSE
Medicamen Organics Ltd
HealthcareNSE: MEDIORG Pharmaceuticals
Key Fundamentals
SMEPharmaceuticalsHealthcareMarket Cap
₹29.62 Cr
Volatility
Moderate
P/E Ratio
-7.4
EBITDA
₹-3.75 Cr
Return on Equity
13.28%
Debt to Equity
0.5
Book Value
₹23.61
52W High
₹41
52W Low
₹19.1
Insights
BetaAI-extracted from concalls & annual reports · figures as reported, with sources
Log in to view Medicamen Organics Ltd insights
37 extracted metrics + investor summaries across FY22–FY26.
Tapetide Score
Data-driven rating, 0–100. How it works →
Technical Indicators
Key Insights
Strengths
1- Stock is trading at 1.03 times its book value
Weaknesses
6- Company has low interest coverage ratio.
- Promoter holding has decreased over last quarter: -6.38%
- Company has a low return on equity of 3.01% over last 3 years.
- Company might be capitalizing the interest cost
- Company has high debtors of 300 days.
- Working capital days have increased from 144 days to 223 days
Growth Rate
Revenue Growth
-40.91% ↗
Net Income Growth
-232.00% ↘
Cash Flow Change
-24.04% ↘
ROE
-22.79% ↘
ROCE
-38.67% ↘
EBITDA Margin (Avg.)
-194.61% ↘
Quarterly Results
| Mar 2024 | Sep 2024 | Mar 2025 | Sep 2025 | Mar 2026 | |
|---|---|---|---|---|---|
| Sales | 13.95 | 16.61 | 21.58 | 17.85 | 4.78 |
| Expenses | 11.62 | 13.88 | 17.73 | 14.43 | 11.95 |
| Operating Profit | 2.33 | 2.73 | 3.85 | 3.42 | -7.17 |
| OPM % | 16.7% | 16.44% | 17.84% | 19.16% | -150% |
| Other Income | 0.01 | 0.04 | 0.05 | 0.06 | 0.02 |
| Interest | 0.36 | 0.22 | 0.29 | 0.33 | 0.38 |
| Depreciation | 0.36 | 0.36 | 0.37 | 0.41 | 0.48 |
| PBT | 1.62 | 2.19 | 3.24 | 2.74 | -8.01 |
| Tax % | 22.84% | 30.59% | 21.6% | 25.55% | -24.47% |
| Net Profit | 1.26 | 1.51 | 2.54 | 2.04 | -6.06 |
| EPS in Rs | 1.47 | 1.29 | 2.17 | 1.74 | -4.98 |
Profit & Loss
| Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|
| Sales | 25.27 | 38.19 | 22.63 |
| Expenses | 20.53 | 31.58 | 26.38 |
| Operating Profit | 4.74 | 6.61 | -3.75 |
| OPM % | 18.76% | 17.31% | -16.57% |
| Other Income | 1.07 | 0.1 | 0.08 |
| Interest | 0.65 | 0.54 | 0.71 |
| Depreciation | 0.72 | 0.74 | 0.9 |
| PBT | 4.44 | 5.43 | -5.28 |
| Tax % | 40.77% | 25.41% | -23.86% |
| Net Profit | 2.62 | 4.05 | -4.02 |
| EPS in Rs | 3.05 | 3.46 | -3.3 |
| Div. Payout % | 0% | 0% | 0% |
Balance Sheet
| Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|
| Equity Capital | 8.6 | 11.7 | 12.17 |
| Reserves | 6.66 | 18.43 | 16.56 |
| Borrowings | 12.66 | 12.35 | 14.3 |
| Other Liabilities | 10.52 | 16.73 | 8.6 |
| Total Liabilities | 38.44 | 59.21 | 51.63 |
| Fixed Assets | 10.35 | 10.13 | 13.37 |
| CWIP | 0.15 | 2.22 | 0.09 |
| Investments | 0 | 0 | 0 |
| Other Assets | 27.94 | 46.86 | 38.17 |
| Total Assets | 38.44 | 59.21 | 51.63 |
Cash Flow
| Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|
| Operating | -3.66 | -4.54 | -4.6 |
| Investing | -0.34 | -2.35 | -1.72 |
| Financing | 4.01 | 10.47 | 3.48 |
| Net Cash Flow | 0.01 | 3.58 | -2.83 |
| Free Cash Flow | -4.01 | -6.99 | -6.34 |
| CFO/OP | -73 | -67 | 119 |
Ratios
| Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|
| Debtor Days | 241 | 247 | 300 |
| Inventory Days | 244 | 228 | 243 |
| Days Payable | 282 | 357 | 129 |
| Cash Conversion Cycle | 204 | 119 | 415 |
| Working Capital Days | 74.24 | 135 | 223 |
| ROCE % | — | 16.88% | -10.66% |
Documents
1
Cessation
21 Jul - Executive Director Brijesh Kumar Chaubey resigned effective July 20, 2026, citing family medical issues. 21 Jul - Executive Director Brijesh Kumar Chaubey resigned effective July 20, 2026, citing family medical issues.
2
Resignation of Director/KMP/SMP
21 Jul - Medicamen Organics Limited has informed about Resignation of Director/KMP/SMP 21 Jul - Medicamen Organics Limited has informed about Resignation of Director/KMP/SMP
3
Resignation of Director/KMP/SMP
21 Jul - Medicamen Organics Limited has informed about Resignation of Director/KMP/SMP 21 Jul - Medicamen Organics Limited has informed about Resignation of Director/KMP/SMP
4
Certificate under SEBI (Depositories and Participants) Regulations, 2018
9 Jul - Submitted Regulation 74(5) certificate for quarter ended June 30, 2026; no demat/remat requests processed. 9 Jul - Submitted Regulation 74(5) certificate for quarter ended June 30, 2026; no demat/remat requests processed.
5
Committee Meeting Updates
9 June 2026 - Allotted 27.14 lakh shares and 11.86 lakh warrants for ₹13.65 crore on June 9, 2026. 9 June 2026 - Allotted 27.14 lakh shares and 11.86 lakh warrants for ₹13.65 crore on June 9, 2026.
Frequently Asked Questions about Medicamen Organics Ltd
What does Medicamen Organics Ltd do?
Incorporated in 1995, Medicamen Organics Ltd develops, manufactures, and distributes a broad range of pharmaceutical dosages including generic dosage[1]
Where is Medicamen Organics Ltd (MEDIORG) listed?
Medicamen Organics Ltd is listed on the Indian stock exchanges. It is listed on NSE: MEDIORG. You can view its live share price, financials, and ratios on Tapetide.
Which sector does Medicamen Organics Ltd belong to?
Medicamen Organics Ltd operates in the Healthcare sector within the Pharmaceuticals industry. Sector classification helps investors compare companies affected by similar economic conditions and regulatory changes.
What is the market capitalisation of Medicamen Organics Ltd?
Medicamen Organics Ltd has a market capitalisation of approximately ₹29.62 Cr. Based on this, it is classified as a Small Cap stock.
What is the PE ratio of Medicamen Organics Ltd?
The Price-to-Earnings (PE) ratio of Medicamen Organics Ltd is -7.40. The PE ratio compares a company's share price to its earnings per share and is commonly used to assess whether a stock is overvalued or undervalued relative to its peers.
What is the 52-week high and low of Medicamen Organics Ltd?
Over the past 52 weeks, Medicamen Organics Ltd has traded between a low of ₹19.1 and a high of ₹41. This range helps investors understand the stock's price volatility and recent trading levels.
What is the Return on Equity (ROE) of Medicamen Organics Ltd?
Medicamen Organics Ltd has a Return on Equity (ROE) of 13.28%. ROE measures how effectively a company uses shareholders' equity to generate profits. A higher ROE generally indicates better capital efficiency.
How can I research Medicamen Organics Ltd on Tapetide?
On Tapetide, you can view Medicamen Organics Ltd's live share price, quarterly results, profit & loss statements, balance sheet, cash flow, key ratios, shareholding pattern, technical indicators, analyst ratings, and forecasts — all on a single page without needing to sign up.
Company Information
Incorporated in 1995, Medicamen Organics Ltd develops, manufactures, and distributes a broad range of pharmaceutical dosages including generic dosage[1]